The comparison of two different chemotherapy programs in the treatment of refractory breast cancer patients

10th Mediterranean Congress of Chemotherapy -- OCT 20-25, 1996 -- ANTALYA, TURKEYWOS: A1996BG90P00095Sixty metastatic and recurrent breast cancer patients who had been given CMF therapy previously and had applied to the Ongology Departments of Cukurova and Ege University Medical Schools between March 1992-94, have been randomized into 2 groups for the chemotherapy program. The 30 patients in the 1(st) group were given Etoposide: 200mgxdayx5 orally every 3 weeks. in the 2(nd) group Fluorouracil:500 mgxm(2) ,Doxorubicin:50mg/m(2), Cyclophosphamide:500mg/m(2) were administered intravenously every 3 weeks. The response rates were 22/30 in the 1(st) group and 18/30 in the 2(nd) group. The duration of responses were 11 months (8-21) in the 1(st) and 9 months (4-18) in the 2(nd) group. Severe myelotoxicity was observed in 2 of the patients in the 1(st) group and in 5 of the patients in the 2(nd) group

Clinical-Evaluation of Metastases of Malignant-Melanoma Imaging With Tc-99(M)-Glutathione and Tc-99(M)-Anti-Melanoma Antibody - a Comparative-Study

WOS: A1995TE34900009PubMed ID: 8587759The aim of this investigation was to test for the scintigraphic detection of metastases of malignant melanoma with a new radiopharmaceutical, Tc-99(m)-glutathione (Tc-99(m)-GSH), in comparison with Tc-99(m)-anti-melanoma antibody (Tc-99(m)-AMAb). Glutathione was labelled with Tc-99(m) by a Sn2+ reduction method with an efficiency of > 99% as determined by instant thin layer chromatography (ITLC). Anti-melanoma antibody was obtained as a kit from SORIN (Italy) and labelled with (TcO4-)-Tc-99-O-m. Forty-three patients with a total of 55 biopsy-proven metastatic melanoma foci, 1 ocular melanoma and 20 benign pathologic foci, also confirmed by ultrasound, computed tomography and magnetic resonance imaging, were included in the study after giving their informed consent. Following the intravenous (i.v.) injection of 500 MBq Tc-99(m)-AMAb, scintigraphic images of the involved areas were obtained 6 h post-injection. Three days later, the same patients were given 500 MBq Tc-99(m)-GSH i.v, and images were obtained 6 and 24 h post-injection. The images were classified as positive (focal abnormal accumulation) or negative. Quantitative evaluation was also applied. Regions of interest were drawn over the involved areas and nearby soft tissues and the target-to-nontarget (T/NT) ratios obtained with Tc-99(m)-AMAb (T/NT: 1.92 +/- 0.2) and Tc-99(m)-GSH (T/NT: 1.84 +/- 0.2) were compared (0.1 < P less than or equal to 0.3). The sensitivity (and specificity) of Tc-99(m)-AMAb and Tc-99(m)-GSH in the detection of malignant melanoma metastases were 91% (95%) and 84% (90%), respectively. Compared with Tc-99(m)-AMAb, the advantages of Tc-99(m)-GSH are lower levels of blood radioactivity, lower costs and easy in-house preparation. In conclusion, our results show that Tc-99(m)-GSH is a potentially useful radiopharmaceutical for the detection of metastases of malignant melanoma